Manava+ is a Biology and AI company building a world without paralysis. Addressing the 170 million people globally with broken neural circuits from conditions like Stroke, Spinal Cord Injury, and Traumatic Brain Injury, the company is creating a new therapeutic class to restore lost function. Instead of bypassing an injury, Manava+’s core technology builds a new, intelligent, and living pathway directly through it. The company’s platform is a fully autonomous, implantable neuroprosthesis that combines two key elements: a living neural organoid cultured from the patient’s own tissue to act as a biological bridge, and a neuromorphic chip that serves as an adaptive AI to make it functional. This integrated approach is designed to restore both motor and sensory functions. The company’s science is significantly de-risked. To date, Manava+ has: Secured €7.5M in non-dilutive government grants. Validated its functional hardware prototypes with proven biocompatibility. Successfully implanted living human neural organoids into in-vivo animal models. Developed a predictive AI engine trained on a proprietary dataset from over 250 human organoids. Manava+ has a capital-efficient and accelerated go-to-market strategy, targeting First-in-Human validation years ahead of schedule by leveraging compassionate use programs.
